To Evaluate the Safety/Tolerability and Pharmacokinetic Characteristics in Healthy Volunteers
A Randomized, Double-blind, Placebo-controlled, Single Ascending Dose, Phase 1 Clinical Trial to Evaluate the Safety/Tolerability and PK Characteristics, and to Explore Food Effect and Ethnic Difference of JW2286 in Healthy Volunteers
JW Pharmaceutical
72 participants
Jan 6, 2025
INTERVENTIONAL
Conditions
Summary
This clinical trial is a randomized, double-blind, placebo-controlled, single ascending dose, phase 1 clinical trial to evaluate the safety/tolerability and pharmacokinetic characteristics, and to explore food effect and ethnic difference of JW2286 after oral administration in healthy adults.
Eligibility
Inclusion Criteria1
- Healthy Korean or Caucasian volunteers
Exclusion Criteria3
- Individuals with a clinically significant disease or history
- Individuals with a history of a gastrointestinal disorder or surgery
- In the case of all female individuals with childbearing potential, except for those who are surgically sterile
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
a single administration of JW2286 per dose
a single administration of Placebo of JW2286 per dose
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06703710